Some of the biggest changes that are expected to happen in the clinical trials industry in next couple of years are going to be driven by technology. Digital platforms and smart applications are going to be used to procure informed consent from the participants, store information, and conduct other critical tasks. The growing ability of AI to probe patient data - including medical histories, labs, scans, clinician notes, and other documentation - points to the growing role that RWD will play in health innovation moving forward.
PROGRAM
Moderator: Kirsti Nyhus, CEO and Market access director in AbbVie
- Clinical trials in Norway today, Siri Kolle Vice President Clinical, Inven2
- Trends and needs in Clinical Trials, Andreas Heddini, Vice President Medical and Regulatory Affairs, Nordics, AstraZeneca
Comments/Panel discussion:
What are the opportunities for Clinical Trials in Norway given the global trends and what priorities do we have to make to increase clinical trial activity in Norway?
Participants:
- Karl Kristian Bekeng, State Secretary, The Ministry of Health and Care Services (HOD)
- Fredrik Schjesvold, Head of Oslo Myeloma Center; PhD, MD Oslo University Hospital
- Peder Langeland Myhre F?rsteamanuensis - Klinikk for indremedisin og lab fag, Akershus universitetssykehus
The event is organized by
 |
 |
 |
 |
 |
 |